HPV is the wild card - ssb have factored into their 12 month...

HPV is the wild card - ssb have factored into their 12 month estimate of $41 plus a gain of 15 - 20 million in 2nd half 2006 for HPV royalities.

Your post :

This year (FY 05) profit will be above $500m with a oneoff of $200m capital gain. This is a far cry from $70mil, 2 years ago.
With FDA approval early next year for HPV then a oneoff bonus payment from Merck comes in.
Are we looking at a cheap (PE) company as this one-off have not been factored in?
After all once HPV vaccine hits the market an extra 150-200m annual addition on profit is on the card as well...


____________________________________________


where are you pulling the $150 - 200 million from ?


singas